Overview

Patient-Reported Outcome Of Facial Erythema (PROOF)

Status:
Completed
Trial end date:
2013-11-14
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness). The feedback of patients receiving the active drug will be compared to the feedback of patients receiving the placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Galderma
Galderma R&D
Treatments:
Brimonidine Tartrate